Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allied Labs

This article was originally published in The Tan Sheet

Executive Summary

Minneapolis-based OTC drug manufacturer corrects cGMP problems cited in a Nov. 2 FDA warning letter. Violations included "failure to calibrate instruments...at suitable intervals" and "failure of...laboratory records to include complete data derived from all tests necessary to assure compliance with established specifications." In a Nov. 23 correspondence, FDA notes the firm's "responses appear to adequately address the observations...listed in the warning letter." Goldberg Consulting, which acquired Allied Labs in July, said major changes are being implemented at the Allied facilities. The firm contract manufactures items such as dentifrices and mouthrinses
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS090775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel